Stock MYND MYND LIFE SCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials MYND Life Sciences Inc.

Equities

MYND

CA62857B1094

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 14:30:00 08/05/2024 BST 		5-day change 1st Jan Change
0.04 CAD 0.00% Intraday chart for MYND Life Sciences Inc. +14.29% 0.00%
03-21 MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
03-04 MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2023 CI

Valuation

Fiscal Period: October 2021 2022 2023
Capitalization 1 45.47 3.745 0.7173
Enterprise Value (EV) 1 45.9 6.331 3.717
P/E ratio -10.2 x -1.05 x -0.47 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA -10,623,348 x -1,224,541 x -392,977 x
EV / FCF - -3,953,563 x -769,525 x
FCF Yield - -0% -0%
Price to Book -669 x -1.06 x -0.14 x
Nbr of stocks (in thousands) 45,933 46,817 47,817
Reference price 2 0.9900 0.0800 0.0150
Announcement Date 28/02/22 28/04/23 04/03/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: October 2019 2020 2021 2022 2023
Net sales - - - - -
EBITDA - - -4.281 -3.059 -1.825
EBIT 1 -0.002535 -0.000694 -4.292 -3.063 -1.829
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -0.002535 -0.000694 -4.536 -3.697 -1.518
Net income 1 -0.002535 -0.000694 -4.367 -3.567 -1.518
Net margin - - - - -
EPS 2 -0.001486 -0.000098 -0.0971 -0.0764 -0.0321
Free Cash Flow - - - -0.9473 -0.9321
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 01/12/20 01/12/20 28/02/22 28/04/23 04/03/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: October 2019 2020 2021 2022 2023
Net Debt - - 0.42 2.59 3
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - -0.0989 x -0.8454 x -1.644 x
Free Cash Flow - - - -0.95 -0.93
ROE (net income / shareholders' equity) - 31.9% 7,184% 198% 35.7%
ROA (Net income/ Total Assets) - - -201% -115% -157%
Assets 1 - - 2.174 3.097 0.9639
Book Value Per Share 2 -0 -0 -0 -0.0800 -0.1000
Cash Flow per Share - - 0.0400 0 0
Capex - - 0.04 - -
Capex / Sales - - - - -
Announcement Date 01/12/20 01/12/20 28/02/22 28/04/23 04/03/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MYND LIFE SCIENCES INC. Stock MYND Life Sciences Inc.
0.00% 1.39M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.69% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.07% 105B
ARGENX SE Stock argenx SE
+1.57% 23.46B
BIONTECH SE Stock BioNTech SE
-11.99% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.64% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.87% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.03% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.16% 12.53B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MYND Stock
  4. Financials MYND Life Sciences Inc.